Cephradine compacted grade at 250 mg and 500 mg dose ranges is processed by direct compression only when the API is milled to a D90 below <200 µm and conditioned to a Hausner ratio below 1.35. The blend is composed of cephradine compacted API at 55–70% w/w, microcrystalline cellulose at 20–30% w/w, crospovidone at 3–6% w/w, colloidal silicon dioxide at 0.5–1.0% w/w, and magnesium stearate at 0.5–1.0% w/w; the microcrystalline cellulose fraction is adjusted to normalise the formula to 100.0% when API load shifts between the two label strengths. The powder is first passed through a 1.0 mm oscillating sieve, blended with excipients in a bin blender at 8–12 rpm for 15–25 min, and then lubricated for 3–5 min before compression. Direct compression is preferred because the API is susceptible to hydrolytic degradation if wet granulation is introduced without need; therefore the blend is maintained below 2.0% water by Karl Fischer USP <921> Method I and is not exposed to temperatures above 40°C during blending.

On a production rotary press, a precompression force of 4–6 kN and main compression force of 10–18 kN are applied to achieve tablet hardness of 70–120 N. Tablet hardness above 120 N delays disintegration beyond the 15 min acceptance threshold, while hardness below 70 N raises friability above <1.0% and produces edge damage during film coating. The finished product is an immediate-release film-coated cephradine tablet at 250 mg and 500 mg label claim, released against the compendial monograph with assay and content uniformity by USP <905>, dissolution by USP <711> in 0.1 N HCl at 50 rpm, disintegration by USP <701>, and friability by USP <1216>. In-process controls for weight, thickness, and hardness are aligned with 21 CFR 211.113, and the terminal oral dosage form is supplied as an immediate-release solid tablet for general oral administration.

Why Does Powder Flow Function Outrank Bulk Density in High-Speed Capsule Filling?

The distinction between cephradine compacted and undensified milled API becomes measurable at the tamping station of an intermittent-motion capsule filler. Capsule formulations for 250 mg and 500 mg cephradine are prepared with compacted API at 60–75% w/w, lactose monohydrate or pregelatinized starch at 15–30% w/w, crospovidone at 2–4% w/w, and magnesium stearate at 0.25–0.75% w/w; colloidal silicon dioxide may be added at 0.25–0.50% w/w by removing an equal fraction of diluent. Fill weight is held at 335–415 mg for 250 mg strength and 670–830 mg for 500 mg strength. Bulk density must remain between 0.45 g/mL and 0.60 g/mL, and the Hausner ratio must stay below 1.35; if flow function drops, dosator weight RSD exceeds 3.0% and the fill misses the weight variation limit of USP <905>. Production is run on a dosator or tamping-pin capsule filler with powder bed depth maintained between 50 mm and 80 mm; tamping force is adjusted within 50–200 N to achieve consistent plug density without causing powder bridging in size 0 or 1 hard gelatin capsules. Release testing includes dissolution by USP <711> in 0.1 N HCl, moisture by USP <921> Method I below 3.0%, and content uniformity by USP <905>. The terminal dosage form is a two-piece hard gelatin or HPMC capsule for immediate-release oral administration, with both 250 mg and 500 mg presentations as commercial units.

Bridging and ratholing are the primary failure modes when the lubricant is overblended. Magnesium stearate contact time beyond 10 min in a bin blender at 8–12 rpm reduces water penetration into the plug and can shift dissolution Q at early pull points. This is the production boundary that separates capsule-suitable cephradine powder from tablet-suitable cephradine powder, and it is controlled by reducing lubricated blend time rather than by increasing disintegrant loading.

Fines Migration and Sedimentation Control in Dry Syrup Granules

In cephradine powder for oral suspension, the formulation target is not compacted tablet strength but reconstitution homogeneity after a patient-level shake cycle. The dry powder is formulated with cephradine compacted API at 8–20% w/w for a reconstituted strength of 125 mg/5 mL or 250 mg/5 mL, combined with sucrose or sorbitol as the soluble diluent, xanthan gum at 0.2–0.5% w/w, sodium carboxymethylcellulose at 0.3–0.8% w/w, sodium benzoate at 0.05–0.1% w/w, and a citric acid/phosphate buffer to maintain final pH at 4.5–5.5 after reconstitution. The granulation is performed by wet massing the API and diluent in a high-shear granulator until the mass passes the 1.0 mm screen endpoint; the wet granulate is dried in a tray dryer at 50–60°C to a loss-on-drying of <1.5%, then sieved through 16–20 mesh to strip oversized agglomerates and preserve redispersibility. The dried granules are filled into HDPE bottles with desiccant and child-resistant closures; fill weight is calculated to deliver the labelled volume of 60 mL or 100 mL after reconstitution, with deliverable volume checked against USP <698> and pH against USP <791>. Preservative effectiveness is verified by USP <51>; residual moisture is controlled by USP <731> and USP <921> Method I because free water above 1.5% pre-hydrates xanthan gum in the bottle and causes gelling during storage. The terminal finished product is a single-dose or multi-dose powder for oral suspension delivering 125 mg/5 mL or 250 mg/5 mL cephradine after reconstitution with purified water.

Fines migration during bottle filling is mitigated by the granule density envelope. If the granule bulk density falls below 0.45 g/mL, API-rich fines segregate to the top of the bottle and the first reconstituted dose may exceed assay limits, while the last dose may fall below label strength. The process is therefore controlled by filled-volume weight, granule density, and sieve profile rather than by powder flow alone.

Because cephradine contains a beta-lactam ring and cannot be terminally sterilised by steam without degrading to inactive open-ring products, sterile injectable API is produced from micronized cephradine by aseptic crystallisation and/or sterile micronisation followed by low-humidity drying and filling under ISO 13408-1 conditions. The vial fill is not a proportioned blend: each vial receives cephradine powder corresponding to 500 mg or 1 g label claim, and the formulation addition is therefore 100.0% of the declared label claim as sterile cephradine powder; no compression excipient ratio applies to the active fill, and any buffer is added only after a separate stability study. Moisture is held below 2.0% by USP <921> Method I and residual solvents are controlled by USP <467>. The sterile powder is filled in Grade A localised air with continuous particulate monitoring; vial and stopper components are washed and depyrogenated before use, and the headspace is purged with sterile filtered nitrogen where residual oxygen may promote colour body formation. Reconstitution at the point of use is typically to 100–250 mg/mL for intramuscular or intravenous administration; diluent type and volume are fixed per labelling because high-concentration reconstitution can prolong dissolution time and generate visible particles. Release testing for the injection grade includes sterility by USP <71>, bacterial endotoxins by USP <85> with a limit of <0.20 EU/mg, particulate matter by light obscuration USP <788>, visible particulates USP <790>, and container-closure integrity USP <1207>. The finished product is a sterile dry-fill vial of cephradine for injection in 500 mg and 1 g presentations, intended for reconstitution by a healthcare professional immediately before administration.

Process capability is limited by the API’s aqueous solubility and by the beta-lactam degradation rate in humid air. Exposure time after sterile drying is therefore constrained by the validated holding time, and the aseptic fill line is segregated from oral-grade production to prevent cross-contamination. Filling pump components are selected for low-shear dry powder transfer because fine powder compaction in the dosing wheel can raise fill weight variability beyond the in-process limit established for the batch record.

Table 1. Compendial test matrix by cephradine finished dosage form.

When Wet Granulation Addresses Capping in High-Dose Tablet Compaction

If direct compression at 500 mg cephradine dose produces capping at hardness above 90 N, lamination after ejection, or visible edge crumbling at turret speeds above 40 rpm, the formulation is moved to wet granulation. The dry mix is composed of cephradine compacted API at 60–75% w/w, microcrystalline cellulose at 10–20% w/w, crospovidone at 2–5% w/w, croscarmellose sodium at 1–3% w/w, and magnesium stearate at 0.5–1.0% w/w added only after the granulate is dried and milled; the filler fraction is adjusted to bring the total to 100.0%. Povidone K30 at 2–5% w/w is dissolved in purified water and sprayed into the high-shear granulator. Granulation endpoint is controlled by impeller power draw rather than time alone, with impeller speed at 300–800 rpm and chopper speed at 1500 rpm, because the endpoint torque value correlates with granule density and final tablet tensile strength. The wet mass is tray-dried or fluid-bed-dried at 60°C inlet to a loss-on-drying of 1.5–2.5%, then milled through a 1.0–1.5 mm screen before lubrication. Compression is performed with a precompression force of 5–8 kN and main compression force of 15–25 kN; tablet hardness is held at 80–140 N and friability below <0.8% per USP <1216>. The wet-granulated product is released against the same monograph methods: dissolution USP <711>, content uniformity USP <905>, and disintegration USP <701>. The terminal dosage form is a film-coated immediate-release tablet, with an aqueous film coating applied after core compression; residual water above 2.5% after drying is a registered out-of-specification risk because cephradine hydrolysis is moisture-catalysed and can expand the related substances profile beyond the cephradine monograph limit.

This process is considered the fallback route for cephradine tablet manufacturing. It is introduced only when direct compression cannot hold hardness and friability simultaneously. The additional aqueous contact time and drying phase are balanced against the lower capping rate, and the granulation route is qualified for both 250 mg and 500 mg label claims when the formulation is transferred to a new press tooling configuration.